3D Bioprinting
Printing living tissue. A patient's own cells are grown in the lab, mixed into a jelly-like 'bio-ink', and a robotic printer lays it down layer by layer in the shape of the tissue, copied from a scan. Printed skin, cartilage and simple tissues are in clinical use or trials, and printed tissue is used to test drugs. A whole organ is not possible yet, because nobody can print the tiny blood vessels that keep thick tissue alive.
Readiness
Not scored. Watchlist entries do not enter any gradient. WKO Innovation Map 26/27 (2026)
Printing living tissue by depositing bio-inks - living cells suspended in biopolymers - layer by layer into a structure that can be kept alive.
What works today is real and narrower than the headline. Printed skin, cartilage and simple tissue constructs are in clinical use or trials, and printed tissue for drug testing is an established laboratory product. What does not work is the solid organ, and the reason is vasculature: any tissue thicker than a millimetre or two needs a blood supply threaded through it at capillary scale, and printing that network at the resolution cells require, in a structure that survives being connected to a circulation, is the unsolved problem.
Readiness is low on both axes, 4 and 3.5, and the closeness is itself honest. Nobody in this field is overselling to the public; the overselling happens in funding rounds.
Common misconception: that printed organs solve the transplant shortage on a foreseeable timescale. The tissue engineering is decades of work, and the near-term contribution is to drug testing, where it may reduce animal use considerably sooner.
Possibly related megatrends - unreviewed
Unreviewed. Derived from this technology's WKO cluster, not from a judgement about this technology. A starting point for review, not a claim.
Talin, B. (2026). 3D Bioprinting. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/e/3d-bioprinting/